Zobrazeno 1 - 10
of 70
pro vyhledávání: ''
Autor:
Julie Means-Powell, Luis Del Valle, Vandana G. Abramson, Claudia Sorrentino, Melinda Sanders, Ingrid A. Mayer, Debra A. Tonetti, Roohi Ismail-Khan, Samarpan Majumder, Richard M Lush, Lucio Miele
Publikováno v:
Clin Breast Cancer
Preclinical studies have demonstrated a complex cross-talk between Notch and estrogen signaling in ERα-positive breast cancer. Gamma-secretase inhibitors (GSIs) are investigational agents that block the cleavage and activation of Notch receptors. In
Autor:
Sara M. Tolaney, Eric P. Winer, Rebecca Rees, William T. Barry, Shom Goel, Lorenzo Trippa, Laura Spring, Sonia Pernas, Rie K. Tahara, Erica L. Mayer, Chelsea Andrews, Zhenying Tan-Wasielewski, Aditya Bardia
Publikováno v:
Clinical Breast Cancer. 19:399-404
Background Signaling through the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway can mediate therapeutic resistance in HER2-positive breast cancer. Preclinical studies have demonstrated that CDK4/6 inhibitors can resensitize resistant HER2-positive
Autor:
Rui Ge, Yizhao Xie, Leiping Wang, Yannan Zhao, Wei Li, Yinbin Zhang, Yi Li, Biyun Wang, Xichun Hu, Shuqun Zhang, Chengcheng Gong, Xiaoxiang Guan, Jian Zhang, Enying Cao
Publikováno v:
Clinical Breast Cancer. 19:e452-e458
Background Fulvestrant 500 mg and exemestane are widely used agents in first-line therapy for metastatic breast cancer (MBC) of estrogen receptor (ER)-positive (ER+) postmenopausal MBC after failure of adjuvant nonsteroidal aromatase inhibitor (NSAI)
Autor:
Luigi Celio, Claudia Maggi, Giulia Bianchi, Monica Milano, Maria Silvia Cona, Claudio Vernieri, Gabriella Mariani, Marta Brambilla, Alessia Mennitto, Chiara Fabbroni, Elena Farè, Michele Prisciandaro, Filippo de Braud, Sara Cresta, Giuseppe Capri
Publikováno v:
Clinical Breast Cancer. 19:e306-e318
Single-agent gemcitabine is a moderately effective compound in metastatic breast cancer (mBC) treatment. Carboplatin is frequently used in addition to gemcitabine to improve tumor responses, but with an unclear effect on survival outcomes. In this st
Autor:
John D. Hainsworth, John D. Zubkus, Mythili Shastry, Patrick J. Ward, L Finney, Denise A. Yardley, Aruna Mani, Dianna Shipley, Gail Lynn Shaw Wright, Laura M. DeBusk
Publikováno v:
Clinical Breast Cancer. 19:1-9
Background Eribulin mesylate is a non–taxane microtubule inhibitor effective in the treatment of metastatic breast cancer refractory to anthracyclines and taxanes. In preclinical studies, additional mechanisms of eribulin included reversal of epith
Autor:
Rahul Ladwa, Shivanshan Pathmanathan, Jasotha Sanmugarajah, Natasha Woodward, David Wyld, Timothy Kalas
Publikováno v:
Clinical Breast Cancer. 18:e1181-e1187
Maintaining the relative dose intensity (RDI) of adjuvant chemotherapy at ≥ 85% has been associated with improved treatment outcomes in early-stage breast cancer (ESBC). Increasing evidence has suggested that patients aged ≥ 65 years can maintain
Autor:
Yoshimasa Miyagawa, Ayako Bun, Yukie Fujimoto, Tomoko Higuchi, Hiromi Ozawa, Michiko Imamura, Yuichi Takatsuka, Kazuhiro Araki, Ayako Kira, Yasuo Miyoshi, Arisa Nishimukai
Publikováno v:
Clinical Breast Cancer. 18:400-409
Although eribulin and nab-paclitaxel are chemotherapy agents widely used for locally advanced or metastatic breast cancer (MBC), their predictive factors remain unknown. Because the absolute neutrophil-to-lymphocyte ratio (NLR) is a significant progn
Autor:
Stephen T. C. Wong, Kartik Anand, Angel Rodriguez, Tejal Patel, Jenny C. Chang, Polly A. Niravath, Toniva Boone, Joe Ensor
Publikováno v:
Clin Breast Cancer
Chemotherapy eliminates most cancer cells except cancer stem cells. Chloroquine is a potential agent to target cancer stem cells. In this phase II trial for patients with breast cancer who were refractory to anthracycline-based chemotherapy, we combi
Autor:
Robert W. Mutter, Sarah S. Mougalian, Heather B. Neuman, Charles L. Loprinzi, Rachel A. Freedman, Alexis D. Leal, Tufia C. Haddad, Ahmedin Jemal, Lindsey R. Sangaralingham, Kathryn J. Ruddy, Holly K. Van Houten, Cary P. Gross, Nilay Shah, Theresa H.M. Keegan
Publikováno v:
Clinical breast cancer, vol 18, iss 4
BackgroundTreatment-related toxicity can vary substantially between chemotherapy regimens. In this study we evaluated the frequency of outpatient office visits among a cohort of early stage breast cancer survivors after completion of 4 different adju
Autor:
Sharon Wilks, Scot Sedlacek, Praveen K. Reddy, Jagathi D. Challagalla, Mary Ann K Allison, Joyce O'Shaughnessy, Charles F. Eisenbeis, Carlos A. Taboada, Yunfei Wang, Marcus A. Neubauer, Nicholas Koutrelakos, Sasha Vukelja, Cynthia Osborne, Lina Asmar, Frankie A. Holmes
Publikováno v:
Clinical Breast Cancer. 18:e89-e95
Background Hormonal therapies and single-agent sequential chemotherapeutic regimens are the standards of care for HER2 − metastatic breast cancer (MBC). However, treating patients with hormone-refractory and triple negative (TN) MBC remains challen